Multicenter study of outcomes for recurrence following concurrent chemoradiation and durvalumab consolidation in locally advanced, unresectable NSCLC

The PACIFIC trial demonstrated significant overall survival (OS) improvement with the addition of durvalumab consolidation after concurrent chemotherapy and radiation for patients with unresectable stage III non-small cell lung cancer (NSCLC). Despite this advance, the majority of patients do not survive five years. Post-progression outcomes are not well known for patients who have received durvalumab for stage III NSCLC. A multicenter, retrospective study evaluated these outcomes in patients with progression after concurrent chemotherapy and radiation followed by durvalumab consolidation for unresectable disease without known EGFR or ALK alterations. The primary outcomes were progression-free survival 2 (PFS2) and OS from the time of post-durvalumab progression. A total of 190 patients who received durvalumab consolidation were included. Among 91 patients with a progression event after ≥ 1 dose of durvalumab, median PFS2 was 7.9 months and median OS was 12.1 months. Among those with distant recurrence, the most common sites of distant metastasis were CNS, bone, and liver. There were no statistically significant differences in PFS2 or OS based on timing of recurrence (≤1 year versus >1 year) or location of recurrence (local versus distant. The authors conclude that post-progression outcomes are poor among patients with recurrence after treatment with durvalumab consolidation for stage III unresectable NSCLC.